MDSpire - MDSpire Home

The Ophthalmologist

  • July 24, 2026
ER-100 Enters Optic Neuropathy Trial
  • July 24, 2026
  • 2 min
  1. Life Biosciences has initiated a Phase 1 clinical trial for ER-100, targeting optic neuropathies such as open-angle glaucoma and NAION.
  2. The trial will assess the safety and tolerability of ER-100, with endpoints focused on visual function.
  3. ER-100 is the first candidate from Life Biosciences’ Epigenetic Restoration platform, utilizing three transcription factors.
  4. Current treatments for open-angle glaucoma do not address retinal ganglion cell damage, while NAION has no approved therapies.
  5. David Sinclair stated that the study is a significant opportunity to test the impact of restoring epigenetic information on human disease.
...more

The Ophthalmologist

  • July 24, 2026
Digital Phenotyping for Retinal Disease
  • July 24, 2026
  • 3 min
  1. A pilot study evaluated the feasibility of digital phenotyping for patients with inherited retinal diseases using the OverSight app.
  2. The study enrolled 25 patients with retinitis pigmentosa and choroideremia, following them for 12 months.
  3. Participants generated a median of 6,087 steps per day, with older individuals typing significantly slower than younger ones.
  4. Completion rates for patient-reported outcome measures exceeded 70 percent, indicating strong engagement with the app.
  5. The study suggests that digital phenotyping could complement traditional assessments by capturing real-world behavioral changes.
...more

Conexiant

  • July 23, 2026
FDA Approves Zidesamtinib for ROS1 Lung Cancer
  • Kathryn Wighton
  • July 23, 2026
  • 2 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

Conexiant

  • July 23, 2026
Oral Shigella Vaccine Hits 89% Efficacy in Challenge Trial
  • Teraya Smith
  • July 23, 2026
  • 3 min

Objective: To evaluate the efficacy and safety of a live-attenuated oral Shigella sonnei vaccine candidate in a controlled human infection trial. Approach: Tria

...more

Conexiant

  • July 23, 2026
GRAPPA, EULAR Criteria May Identify Complex PsA
  • Andrea Surnit
  • July 23, 2026
  • 3 min

Objective: To evaluate the frequency of patients with early psoriatic arthritis meeting the GRAPPA and EULAR criteria for complex-to-manage and difficult-to-man

...more

The Medicine Maker

  • July 23, 2026
Single-Cell Analysis Reveals Hidden CAR T Manufacturing Risks
  • July 23, 2026
  • 8 min
  1. CAR T therapies are complex and heterogeneous, requiring precise single-cell analytical data to ensure safety and efficacy.
  2. Mission Bio's Tapestri platform enables single-cell analysis of vector copy number, revealing dangerous outliers missed by bulk methods.
  3. Single-cell VCN profiling can detect high-risk cells with VCN >5, which are associated with increased genotoxicity and oncogenesis.
  4. Bulk methods like ddPCR obscure cellular heterogeneity, potentially masking critical safety risks in CAR T products.
  5. Single-cell multiomics links genotype and phenotype, providing comprehensive insights into the quality and functionality of CAR T therapies.
...more

The Ophthalmologist

  • July 23, 2026
Could HPV Be a Risk Factor for Uveitis?
  • July 23, 2026
  • 3 min
  1. A history of HPV infection may increase the risk of developing uveitis, according to a retrospective study published in Scientific Reports.
  2. The study analyzed data from over 920,000 adults, including 460,932 with HPV infection and matched controls without HPV.
  3. Patients with HPV infection were found to be 30% more likely to develop uveitis compared to matched controls over a follow-up of up to 15 years.
  4. The association was strongest in men and adults aged 65 years or older, with concurrent herpes zoster infection increasing risk nearly threefold.
  5. The authors caution that findings should be interpreted cautiously due to potential misclassification and inability to establish causality.
...more

The Ophthalmologist

  • July 23, 2026
Exonate Taps Olav Hellebø as EXN407 Nears Phase 2b
  • July 23, 2026
  • 2 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Pathologist

  • July 23, 2026
Careers Uncovered: Veterinary Pathologist
  • Helen Bristow
  • July 23, 2026
  • 4 min
  1. Veterinary pathology became the first officially recognized specialty of veterinary medicine in the USA in 1949.
  2. The American College of Veterinary Pathologists has over 3,000 board-certified members, primarily in the US.
  3. Veterinary pathologists typically work in academia, state diagnostic laboratories, or pharmaceutical companies.
  4. The daily work of veterinary pathologists involves macroscopic examination, histopathology, and immunohistochemistry.
  5. Animal forensic pathology has significantly grown in the past 15 years, with potential for an official subspecialty.
...more

The Pathologist

  • July 23, 2026
Continuous Monitoring Boosts Liver Assessment
  • July 23, 2026
  • 2 min
  1. Continuous biochemical monitoring of donor livers may enhance assessment before transplantation.
  2. A new point-of-care monitoring platform measures pH, glucose, and lactate continuously during liver perfusion.
  3. The system transmits results wirelessly, allowing uninterrupted preservation of donor organs.
  4. Simultaneous analysis of perfusion fluid and bile provides a broader biochemical picture of liver health.
  5. Further research is needed to validate findings and assess the impact on transplant practices.
...more

The Analytical Scientist

  • July 23, 2026
Skin Deep Survival
  • July 23, 2026
  • 3 min

Objective: To investigate the differences in skin peptide defenses among common midwife toad populations recovering from chytrid fungus outbreaks. Approach: Stu

...more

Conexiant

  • July 22, 2026
FDA Expands Pediatric Allergy Nasal Spray Use
  • Kathryn Wighton
  • July 22, 2026
  • 2 min
  1. The FDA has expanded the indication for RYALTRIS nasal spray to include children aged 6 to under 12 years with seasonal allergic rhinitis.
  2. The approval was based on a phase 3 trial with 446 pediatric patients showing greater improvement in nasal symptoms compared to placebo.
  3. RYALTRIS is a fixed-dose combination nasal spray containing olopatadine hydrochloride and mometasone furoate.
  4. The product was initially approved in 2022 for adults and children aged 12 years and older.
  5. Common adverse reactions include dysgeusia, epistaxis, and nasal discomfort, with warnings for various serious conditions.
...more

Conexiant

  • July 22, 2026
CLDN18.2 May Define Lung Adenocarcinoma Phenotype
  • Andrea Surnit
  • July 22, 2026
  • 3 min
  1. CLDN18.2 was expressed in 61% of pulmonary invasive mucinous adenocarcinomas, with high expression in 36% of tumors.
  2. The study evaluated 117 tumors from patients who underwent curative-intent surgical resection between 2018 and 2020.
  3. CLDN18.2 expression correlated with gastric-type mucin differentiation, with 90% of CLDN18.2-positive tumors expressing MUC5AC.
  4. The study found no significant association between CLDN18.2 or MUC5AC expression and overall survival.
  5. The authors noted limitations including a small cohort and called for multicenter prospective studies to explore CLDN18.2's therapeutic relevance.
...more

Conexiant

  • July 22, 2026
Medical Oddities: When AI Meets the Afterlife
  • Teraya Smith
  • July 22, 2026
  • 4 min
  1. University of Colorado Boulder researchers studied responses to AI chatbots simulating conversations with deceased loved ones.
  2. Participants preferred chatbots that spoke as the deceased, finding them more emotionally impactful than third-person versions.
  3. Users prioritized the chatbot's ability to mimic a loved one's tone over factual accuracy during interactions.
  4. Concerns arose that frequent use of lifelike AI could complicate the grieving process and create emotional dependence.
  5. The study suggests that while AI can create a digital afterlife, true emotional connection resides in users' memories.
...more

Conexiant

  • July 22, 2026
Uric Acid May Signal Coronary Calcification
  • Andrea Surnit
  • July 22, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

Conexiant

  • July 22, 2026
Ixekizumab May Improve Early Response After Secukinumab Failure
  • Andrea Surnit
  • July 22, 2026
  • 4 min
  1. Ixekizumab showed faster early skin responses than guselkumab or ustekinumab after secukinumab treatment failure in a real-world cohort.
  2. 67% of patients switching to ixekizumab achieved PASI 75 at week 12, compared to 28% with guselkumab and 17% with ustekinumab.
  3. The study evaluated 59 patients with moderate-to-severe plaque psoriasis who switched biologics due to treatment failure or adverse events.
  4. Safety profiles were similar across all treatment groups, with 20% of patients experiencing mild adverse events.
  5. Subgroup analyses indicated that treatment history may influence response to biologic switching, though findings were not statistically significant.
...more

Conexiant

  • July 22, 2026
BiZact May Improve Adult Tonsillectomy Recovery
  • Andrea Surnit
  • July 22, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

Conexiant

  • July 22, 2026
Trump’s Personnel Agency Says It Will Remove Some Identifying Info as It Sweeps Up Medical Records
  • Amanda Seitz
  • Maia Rosenfeld
  • Darius Tahir
  • July 22, 2026
  • 7 min
  1. The Trump administration plans to collect medical records of over 8 million federal workers, retirees, and their families.
  2. The Office of Personnel Management will pseudonymize personal health information before analysis, but retains the right to reidentify records.
  3. Sixty-five insurance companies will provide detailed health data to OPM to help identify fraud in federal health benefit programs.
  4. Concerns about privacy persist, with critics arguing that pseudonymization may not sufficiently protect sensitive information.
  5. OPM's plan includes analyzing records from Medicare for dual enrollees to enhance fraud detection efforts.
...more